ArticleACS omega2026
Research on the Molecular Mechanism of Ginsenoside Ro in Neuronal Damage Following Subarachnoid Hemorrhage.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have demonstrated the anti-inflammatory, antidepressant, and neuroprotective effects of Ginsenoside Ro. Subarachnoid hemorrhage (SAH), a stroke subtype characterized by bleeding into the subarachnoid space following rupture of intracranial vessels, results in early brain injury (EBI), which critically influences prognosis. Currently, specific treatments for SAH-induced EBI are lacking. This study aimed to investigate the mechanism by which Ginsenoside Ro ameliorates neural injury following SAH, utilizing network pharmacology, molecular docking, qRT-PCR, and Western blot. In this study, we identified 88 common interaction targets between Ginsenoside Ro and SAH. Protein-protein interaction (PPI) network analysis revealed core targets, including TNF-α, EGFR, Bcl-2, SRC, and MMP9. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses indicated that these targets are involved in biological processes such as apoptosis, inflammatory response, and blood-brain barrier repair, primarily modulating the MAPK, PI3K-Akt, and estrogen signaling pathways. Molecular docking confirmed strong binding affinity between Ginsenoside Ro and the core targets SRC, EGFR, MMP9, and Bcl-2. Results demonstrated that Ro significantly modulates the expression of EGFR and Bcl-2, and Ginsenoside Ro could significantly enhance cell viability. These findings suggest that Ginsenoside Ro may mitigate SAH-induced neural injury by regulating the EGFR and Bcl-2 pathways, providing a theoretical foundation for potential clinical applications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.